Meeting
2019 ASCO Annual Meeting
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma.
Authors
Haeseong Park
Washington University School of Medicine, St. Louis, MO
Haeseong Park , Nikolaos Trikalinos , Aravind Sanjeevaiah , Katrina Pedersen , Nusayba Ali Bagegni , Andrew B. Nixon , Jesse Huffman , Benjamin R. Tan Jr., Rama Suresh , Kian-Huat Lim , Manik A. Amin , Andrea Wang-Gillam , A. Craig Lockhart
Disclaimer
This material on this page is ©2024 American Society of Clinical Oncology, all rights reserved. Licensing available upon request. For more information, please contact licensing@asco.org
Poster Details
Session Type
Poster Session
Session Title
Gastrointestinal (Noncolorectal) Cancer
Track
Gastrointestinal Cancer—Gastroesophageal, Pancreatic, and Hepatobiliary
Sub Track
Esophageal or Gastric Cancer
Clinical Trial Registration Number
NCT03141034
Citation
J Clin Oncol 37, 2019 (suppl; abstr TPS4150)
DOI
10.1200/JCO.2019.37.15_suppl.TPS4150
Abstract #
TPS4150
Poster Bd #
250b
Abstract Disclosures
Similar Posters
Poster
2022 ASCO Gastrointestinal Cancers Symposium
Ramucirumab and irinotecan in patients with previously treated gastroesophageal adenocarcinoma: Final analysis of a phase II trial.
First Author: Haeseong Park
Poster
2022 ASCO Gastrointestinal Cancers Symposium
BREAKWATER safety lead-in (SLI): Encorafenib + cetuximab (EC) ± chemotherapy for first-line (1L) treatment (tx) of BRAF V600E-mutant (BRAFV600E) metastatic colorectal cancer (mCRC).
First Author: Scott Kopetz
Poster
2021 Gastrointestinal Cancers Symposium
RAINBOW-Asia: A randomized, multicenter, double-blind, phase III study of ramucirumab plus paclitaxel versus placebo plus paclitaxel in the treatment of advanced gastric or gastroesophageal junction (GEJ) adenocarcinoma following disease progression on first-line chemotherapy with platinum and fluoropyrimidine.
First Author: Rui-hua Xu
Poster
2019 ASCO Annual Meeting
Assessment of Ramucirumab plus paclitaxel as switch maintenance versus continuation of first-line chemotherapy In patients (pts) with advanced HER-2 negative gastric or gastroesophageal junction cancers: The ARMANI phase III trial.
First Author: Federica Morano